High-dose aciclovir in CMV infection prophylaxis after
allogeneic HSCT: a single-center long-term experience

ENPřihlásit se Přihlásit se (EduID)

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term ...

Přehled o publikaci

J 2023

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience

KABUT, Tomáš, Barbora WEINBERGEROVÁ, František FOLBER, Martina LENGEROVÁ, Jiří MAYER et. al.

Základní údaje

Originální název

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience

Autoři

KABUT, Tomáš, Barbora WEINBERGEROVÁ, František FOLBER, Martina LENGEROVÁ a Jiří MAYER

Vydání

Bone Marrow Transplantation, LONDON, SPRINGERNATURE, 2023, 0268-3369

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizace

Lékařská fakulta – Masarykova univerzita – Repozitář

DOI

http://dx.doi.org/10.1038/s41409-023-02081-6

UT WoS

001171467900001

EID Scopus

2-s2.0-85168602322

Klíčová slova anglicky

CMV infection; high-dose aciclovir

Návaznosti

LX22NPO5102, projekt VaV.

Změněno: 9. 3. 2024 03:34, RNDr. Daniel Jakubík

Anotace

V originále

lt; 0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir’s adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.

Přiložené soubory

https://is.muni.cz/publication/2348885/High-dose_aciclovir_in_CMV_infection_prophylaxis_after_allogeneic_HSCT_a_single-center_long-term_experience.pdf

Citovat

KABUT, Tomáš, Barbora WEINBERGEROVÁ, František FOLBER, Martina LENGEROVÁ a Jiří MAYER. High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience. Bone Marrow Transplantation. LONDON: SPRINGERNATURE, 2023, roč. 58, č. 11, s. 1229-1236. ISSN 0268-3369. Dostupné z: https://dx.doi.org/10.1038/s41409-023-02081-6.

@article{59926,
   author = {Kabut, Tomáš and Weinbergerová, Barbora and Folber, František and Lengerová, Martina and Mayer, Jiří},
   article_location = {LONDON},
   article_number = {11},
   doi = {http://dx.doi.org/10.1038/s41409-023-02081-6},
   keywords = {CMV infection; high-dose aciclovir},
   language = {eng},
   issn = {0268-3369},
   journal = {Bone Marrow Transplantation},
   title = {High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience},
   url = {https://www.nature.com/articles/s41409-023-02081-6},
   volume = {58},
   year = {2023}
}

TY  - JOUR
ID  - 59926
AU  - Kabut, Tomáš - Weinbergerová, Barbora - Folber, František - Lengerová, Martina - Mayer, Jiří
PY  - 2023
TI  - High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
JF  - Bone Marrow Transplantation
VL  - 58
IS  - 11
SP  - 1229-1236
EP  - 1229-1236
PB  - SPRINGERNATURE
SN  - 0268-3369
KW  - CMV infection
KW  - high-dose aciclovir
UR  - https://www.nature.com/articles/s41409-023-02081-6
N2  - lt; 0.001). The CMV serostatus was the only significant risk factor for CMV infection in our analysis. CMV disease developed in three patients with CMV-related death in two cases. During HD-aciclovir prophylaxis, we did not observe any medical condition attributable to HD-aciclovir’s adverse effects. Compared to published results, we observed a low incidence of cs-CMVi with HD-aciclovir prophylaxis in several patient subgroups, especially in seropositive recipients with a seropositive donor. With respect to the determined threshold, HD-aciclovir prophylaxis seems to have good efficacy in an intermediate cs-CMVi risk patients, but prospective randomized trials would be needed for definite conclusions.
ER  -

KABUT, Tomáš, Barbora WEINBERGEROVÁ, František FOLBER, Martina LENGEROVÁ a Jiří MAYER. High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience. \textit{Bone Marrow Transplantation}. LONDON: SPRINGERNATURE, 2023, roč.~58, č.~11, s.~1229-1236. ISSN~0268-3369. Dostupné z: https://dx.doi.org/10.1038/s41409-023-02081-6.